Genistein suppresses spontaneous oviduct tumorigenesis in quail

Nutrition and Cancer

Volumn 61, Issue 6, 2009, Pages 799-806

  Sahin, Kazim ^a   Akdemir, Fatih ^a   Tuzcu, Mehmet ^a   Sahin, Nurhan ^a   Onderci, Muhittin ^b   Ozercan, Resat ^a   Ilhan, Necip ^a   Kilic, Ertugrul ^c   Seren, Soley ^d   Kucuk, Omer ^d  

^a FIRAT UNIVERSITY   (Turkey)

^b Veterinary Control and Research Institute   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AVIAN PROTEIN; BIOLOGICAL MARKER; CONNEXIN 43; GENISTEIN; ISOFLAVONE DERIVATIVE; PROTEIN BAX; PROTEIN BCL 2;

ANIMAL; ARTICLE; BLOOD; COTURNIX; DOSE RESPONSE; DRUG EFFECT; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; INCIDENCE; LEIOMYOMA; METABOLISM; OVIDUCT; OXIDATIVE STRESS; PATHOLOGY; RANDOMIZATION; TUMOR VOLUME; UTERUS CANCER;

ANIMALS; ANTICARCINOGENIC AGENTS; AVIAN PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BIOLOGICAL MARKERS; CONNEXIN 43; COTURNIX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENISTEIN; GENITAL NEOPLASMS, FEMALE; HUMANS; INCIDENCE; ISOFLAVONES; LEIOMYOMA; OVIDUCTS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; TUMOR BURDEN; UTERINE NEOPLASMS;

EID: 77952490626     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635580903285163     Document Type: Article

References (65)

1. Stewart EA: Uterine fibroids. Lancet 357, 293–298, 2001.
2. Farguhar CM and Steiner CA: Hysterectomy rates in the United States 1990–1997. Obstet Gynecol 99, 229–234, 2002.
3. Cramer SF and Patel A: The frequency of uterine leiomyomas. Am J Clin Pathol 94, 435–438, 1990.
4. Moore AB, Castro LL, Yu X, Zheng X, Di MI, et al.: Stimulatory and inhibitory effects of genistein on human uterine leiomyoma cell proliferation are influenced by the concentration. Hum Reprod 22, 2623–2631, 2007.
5. Englund KA, Blanck I, Gustavsson U, Lundkvist P, Sjoblom A, et al.: Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 83, 4092–4096, 1998.
6. Anderson WI, McCaskey PC, Langheinrich KA, and Dreesen AE: Case report: neurofibrosarcoma and leiomyosarcoma in slaughterhouse broilers. Avian Dis 29, 521–527, 1985.
7. Anjum AD, Payne LN, and Appleby EC: Oestrogen and progesterone receptors and their relationship to histological grades of epithelial tumours of the magnum region of the oviduct of the domestic fowl. J Comp Pathol 100, 275–286, 1989.
8. Foster DN, Nestor KE, Saif YM, Bacon WL, and Moorhead PD: 1989. Influence of selection for increased body weight on the incidence of leiomyomas and leiomyosarcomas in Japanese Quail. Poult Sci 68, 1447–1453, 1989.
9. Kudou S, Fleury Y, Welti D, Magnolato D, Uchida T, et al.: Malonyl isoflavone glycosides in soybean seeds (glycine max Merrill). Agricul Biol Chem 55, 2227–2233, 1991.
10. Giovanucci E: Epidemiological characteristics of prostate cancer. Cancer 75, 1766–1777, 1995.
11. Barnes S, Grubbs C, Setchell KDR, and Carlson J: Soybeans inhibit mammary tumors in models of breast cancer. In: Mutagens and Carcinogens in the Diet, Pariza M (ed.). New York: Wiley-Liss, 1990, pp. 239–253.
12. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, and Wu AH: Kolonel Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146, 294–306, 1997.
13. Davis JN, Singh B, Bhuiyan M, and Sarkar, FH: Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells. Nutr Cancer 32, 123–131, 1998.
14. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, et al.: Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65, 6934–6942, 2005.
15. Giles D and Wei H: Effect of structurally related flavones/isoflavones on hydrogen peroxide production and oxidative DNA damage in phorbol esterstimulated HL-60 cells. Nutr Cancer 29, 77–82, 1997.
16. Li Y and Sarkar FH: Gene expression profiles of genistein-treated PC3 prostate cancer cells. JNutr132, 3623–3631, 2002.
17. Kurzer MS and Xu X: Dietary phytoestrogens. Ann Rev Nutr 17, 353–381, 1997.
18. Zhang JX, Hallmans G, Landstrom M, Bergh A, Damber JE, et al.: Soy and rye diets inhibit the development of Dunning R3327 prostatic adenocarcinoma in rats. Cancer Lett 114, 313–314, 1997.
19. Chen WF and Wong MS:Genistein enhances insulin-like growth factor signaling pathway in human breast cancer (MCF-7) cells. J Clin Endocrinol Metabol 89, 2351–2359, 2004.
20. Le Bail JC, Varnat F, Nicolas JC, and Habrioux G: Estrogenic and antiproliferative activities on MCF-7 human breast cancer cells by flavonoids. Cancer Lett 130, 209–216, 1998.
21. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, et al.: Estrogen receptor alpha mediates the proliferative but not the cytotoxic dosedependent effects of two major phytoestrogens on human breast cancer cells. Mol Pharmacol 60, 595–602, 2001.
22. Kuiper GG, Lemmen JG,Carlsson B, Corton JC, Safe SH, et al.: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139, 4252–4263, 1998.
23. Shushan A, Ben-Bassat H, Mishani E, Laufer N, Klein BY, et al.: Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 87, 127–135, 2007.
24. Berry W, Doernte A, Conner M, Barnes M, and Oates S: Spontaneously occurring fibroid tumors of the laying hen oviduct. Poult Sci 85, 1969–1974, 2006.
25. Coldham NG and Sauer MJ: Pharmacokinetics of [(14) C] Genistein in the rat: gender-related differences, potential mechanisms of biological action, and implications for human health. Toxicol Appl Pharmacol 164, 206–215, 2000.
26. Karatepe M: Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC/UV. LC-GC North America 22, 362–365, 2004.
27. Association of Official Analytical Chemists: Official Methods of Analysis, 15th ed. Arlington VA: Association of Official Analytical Chemists, 1990.
28. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 193, 265–275, 1951.
29. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685, 1970.
30. Baydas G and Tuzcu M: Protective effects of melatonin against ethanolinduced reactive gliosis in hippocampus and cortex of young and aged rats. Exp Neurol194, 175–181, 2005.
31. SAS Institute Inc: SAS User’s Guide: Statistics. Cary, NC: SAS Institute, Inc., 1999.
32. Hunter DS, Hodges LC, Vonier PM, Fuchs-Young R, Gottardis MM, et al.: Estrogen receptor activation via activation function 2 predicts agonism of xenoestrogens in normal and neoplastic cells of the uterine myometrium. Cancer Res 59, 3090–3099, 1999.
33. Nagata C, Takatsuka N, Kawakami N, and Shimizu H: Soy product intake and premenopausal hysterectomy in a follow-up study of Japanese women. Eur J Clin Nutr 55, 773–777, 2001.
34. Knight DC and Eden JA: A review of the clinical effects of phytoestrogens. Obstet Gynecol 87, 897904, 1996.
35. Wei H, Cai Q, and Rahn RO: Inhibition of UV light and Fenton reactioninduced oxidative DNA damage by the soybean isoflavone genistein. Carcinogenesis 17, 73–77, 1996.
36. Shao ZM, Alpaugh M.L, Fontana JA, and Barsky SH: Genistein inhibits proliferation similarly in estrogen receptor-positive and negative human breast carcinoma cell lines characterized by P21WAF1/CIP1 induction, G2/M arrest, and apoptosis. J Cell Biochem 69, 44–54, 1998.
37. Fotsis TM, Pepper H, Adlercreutz G, Fleischmann T, Hase R. et al.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A 90, 2690–2694, 1993.
38. Wong CK and Keung WM: Bovine adrenal 3beta-hydroxysteroid dehydrogenase (E.C. 1.1.1. 145)/5-ene-4-ene isomerase (E.C. 5.3.3.1): charactercharacter ization and its inhibition by isoflavones. J Steroid Biochem Mol Biol 71, 191–202, 1999. ization
39. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinase. JBiolChem 262, 5592–5595, 1987.
40. Okura A, Arakawa H, Oka H, Yoshinari T, and Monden Y: Effect of genistein on topoisomerase activity and on the growth of [val 12] Ha-ras transformed NIH 3T3 cells. Biochem Biophys Res Comm 157, 183–189, 1998.
41. Prasad AS and Kucuk O: Zinc in cancer prevention. Cancer Metas Rev 21, 291–295, 2002.
42. HuangY, Sheu J, and Lin T: Association between oxidative stress and changes of trace elements in patients with breast cancer. Clin Biochem 32, 131–136, 1999.
43. Cai Q and Wei H: Effect of dietary genistein on antioxidant enzyme activities in SENCAR mice. Nutr Cancer 25, 1–7, 1996.
44. Mitchell JH and Collins AR: Effects of a soy milk supplement on plasma cholesterol levels and oxidative DNA damage in men a pilot study. Eur J Nutr 38, 143–148, 1999.
45. Wei H, Wei L, Frenkel K, Bowen R, and Barnes S: Inhibition of tumor promoter-induced hydrogen peroxide formation in vitro and in vivo by genistein. Nutr Cancer 20, 1–12, 1993.
46. Davis JN, Kucuk O, Djuric Z, and Sarkar FH: Soy isoflavone supplementation in healthy men prevents NF-kappa B activation by TNF-alpha in blood lymphocytes. Free Rad Biol Med 30, 1293–1302, 2001.
47. Mokhtar Y, Kamel K, Esmail AM, and Baghdadi HH: Antioxidant activities and lipid lowering effects of isoflavone in male rabbits. Food Chem Toxicol 42, 1497–1503, 2004.
48. El-Demerdash FM, Yousef MI, and Al-Salhen KS: Protective effects of isoflavone on some biochemical parameters affected by cypermethrin in male rabbits. J Environ Sci Health B 38, 365–378, 2003.
49. Yalniz M, Bahcecioglu IH, Kuzu N, Poyrazoglu OK, Bulmus O, et al.: Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 22, 2009–20014, 2007.
50. Wiseman H, O’Reilly JD, Aldercreutz H, Mallet AI, Bowey EA, et al.: Isoflavone phytoestrogens consumed in soy decrease F2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans. Am J Clin Nutr 72, 395–400, 2000.
51. Djuric Z, Chen G, Doerge DR, Heilbrun LK, and Kucuk O: Effect of soy isoflavone supplementation on markers of oxidative stress in men and women. Cancer Lett 172, 1–6, 2001.
52. Dixon D, Flake GP, Moore AB, He H, Haseman JK, et al.: Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 441, 53–62, 2002.
53. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, et al.: Reduced expression of proapoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma, Cancer Res 55, 4471–4478, 1995.
54. Perlman H, Maillard L, Krasinski K, and Walsh K: Evidence for the rapid onset of apoptosis in medial smooth muscle cells after balloon injury. Circulation 95, 981–987, 1997.
55. Wu X, Blanck A, Olovsson M, Henriksen R, and Lindblom B: Expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause J Steroid Biochem Molecular Biol 80, 77–83, 2002.
56. Grummer R, Traub O, and Winterhager E: Gap junction connexin genes cx26 and cx43 are differentially regulated by ovarian steroid hormones in rat endometrium. Endocrinology 140, 2509–2516, 1999.
57. Heikaus S, Winterhager E, Traub O, and Grummer R: Responsiveness of endometrial genes Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor modulators, phyto-and xenoestrogens. J Mol Endocrinol 29, 239–249, 2002.
58. Conklin CM, Bechberger JF, MacFabe D, Guthrie N, Kurowska EM, et al.: Genistein and quercetin increase connexin43 and suppress growth of breast cancer cells. Carcinogenesis 28, 93–100, 2007.
59. Ale-Agha N, Stahl W, and Sies H:-Epicatechin effects in rat liver epithelial cells: stimulation of gap junctional communication and counteraction of its loss due to the tumor promoter 12-otetradecanoylphorbol-13-acetate. Biochem Pharmacol 63, 2145–2149, 2002.
60. Seoane JM, Varela-Centelles PI, Ramirez JR, Cameselle-Teijeiro J, Romero MA, et al.: Heat shock proteins (HSP70 and HSP27) as markers of epithelial dysplasia in oral leukoplakia. Am J Dermatopathol 28, 417–422, 2006.
61. Havik B and Bramham CR: Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines. Oncol Rep 17, 1501–1510, 2007.
62. Li H, Sui C, Kong F, Zhang H, Liu J, et al.: Expression of HSP70 and JNK-related proteins in human liver cancer: potential effects on clinical outcome. Dig Liver Dis 39, 663–670, 2007.
63. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248, 30–43, 1999.
64. Kiang JG and Tsokos GC: Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther 80, 183–201, 1998.
65. Narayanan NK, Narayanan BA, Bosland M, Condon MS, and Nargi D: Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Inter J Cancer 119, 1586–1598, 2006.